newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker